Study guide
5.3 Therapeutic Drug Monitoring (TDM), Narrow Therapeutic Index Drugs & Toxicities
PEBC Pharmacist Qualifying Examination Part I MCQ
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Canadian Pharmacy Regulatory Framework & Federal Legislation
1.1 Food and Drugs Act, Regulations, and Health Canada Oversight 1.2 Controlled Drugs and Substances Act (CDSA) & Controlled Substances Regulations (CSR) 1.3 NAPRA Drug Scheduling Framework & National Model Standards of Practice
2 Chapter 2: Ethics, Scope of Practice & Safety Culture
2.1 Professional Ethics, Fiduciary Duty & Health Information Privacy 2.2 Expanded Scope of Practice: Minor Ailments Prescribing, Renewals & Injections 2.3 Equity, Diversity, Inclusion, Cultural Safety & Continuous Quality Improvement
3 Chapter 3: Pharmaceutical Calculations & Posology
3.1 Concentrations, Dilutions, Alligations & Reconstitution 3.2 Dosing by Weight/BSA, Days Supply & Pediatric/Geriatric Dose Adjustments 3.3 IV Infusion Rates, Drop Factors, Osmolarity & Creatinine Clearance (Cockcroft-Gault)
4 Chapter 4: Compounding, Dispensing & Product Integrity
4.1 Non-Sterile Compounding & Beyond-Use Dating (NAPRA Standards) 4.2 Sterile Preparations & Hazardous Drug Handling (NAPRA / NIOSH Principles) 4.3 Prescription Verification, Auxiliary Labeling, Cold Chain & Medication Incident Prevention (ISMP Canada) 4.4 Dispensing Operations: Interchangeability, Adjudication, Compliance Packaging, Release & Inventory Control
5 Chapter 5: Clinical Pharmacology & Pharmacokinetics
5.1 Pharmacokinetic Principles: Clearance, Volume of Distribution, Half-life & Steady State 5.2 Cytochrome P450 Enzymes, Transporters & Significant Drug-Drug Interactions 5.3 Therapeutic Drug Monitoring (TDM), Narrow Therapeutic Index Drugs & Toxicities
6 Chapter 6: Evidence-Based Medicine & Literature Appraisal
6.1 Study Designs, Bias & Levels of Evidence in Clinical Research 6.2 Biostatistics: ARR, RRR, NNT, NNH, Confidence Intervals & P-values 6.3 Applying Canadian Practice Guidelines to Clinical Decision-Making 6.4 Drug Information Practice, Diagnostic Test Accuracy & Pharmacoeconomics
7 Chapter 7: Cardiovascular Pharmacotherapy: Hypertension, Dyslipidemia & CAD
7.1 Hypertension Management (Hypertension Canada Guidelines, Targets & Regimens) 7.2 Dyslipidemia & Atherosclerotic Cardiovascular Disease (CCS Guidelines & Statin Therapy) 7.3 Ischemic Heart Disease & Acute Coronary Syndromes (Antiplatelet & Antianginal Therapy)
8 Chapter 8: Cardiovascular Pharmacotherapy: Heart Failure, Arrhythmias & Anticoagulation
8.1 Heart Failure with Reduced & Preserved Ejection Fraction (GDMT & Monitoring) 8.2 Atrial Fibrillation, Arrhythmias & Rate vs. Rhythm Control 8.3 Venous Thromboembolism & Anticoagulation Therapy (DOACs, Warfarin & Thrombosis Canada)
9 Chapter 9: Endocrine & Metabolic Disorders
9.1 Type 2 Diabetes: Glycemic Targets, Non-Insulin Pharmacotherapy (Diabetes Canada) 9.2 Insulin Regimens, Type 1 Diabetes, Hypoglycemia & Diabetic Emergencies (DKA/HHS) 9.3 Thyroid Disorders & Osteoporosis (Diagnostic Parameters & Therapeutic Management)
10 Chapter 10: Respiratory & Gastrointestinal Disorders
10.1 Asthma Management & Exacerbations (CTS Guidelines, Relievers & Controllers) 10.2 Chronic Obstructive Pulmonary Disease (COPD) & Inhaler Delivery Systems 10.3 Gastroesophageal Reflux Disease (GERD), Peptic Ulcer Disease & GI Bleeding 10.4 Lower GI & Liver Disorders: Constipation, Diarrhea, IBS, IBD & Cirrhosis
11 Chapter 11: Infectious Diseases & Antimicrobial Stewardship
11.1 Respiratory Tract Infections: Otitis, Sinusitis, Pharyngitis, CAP & HAP 11.2 Urinary Tract, Skin/Soft Tissue & Sexually Transmitted Infections 11.3 Systemic Infections, Clostridioides difficile & Antimicrobial Stewardship Principles 11.4 HIV Prevention & Treatment, Viral Hepatitis, Tuberculosis & Fungal Infections
12 Chapter 12: Central Nervous System & Mental Health
12.1 Major Depressive Disorder & Anxiety Disorders (First-Line Agents & Safety) 12.2 Bipolar Disorder, Schizophrenia & Psychopharmacology Monitoring 12.3 Epilepsy, Seizure Types, Antiseizure Medications & Neuropathic Pain 12.4 Dementia, Parkinson Disease, Migraine, Insomnia & Restless Legs Syndrome
13 Chapter 13: Special Populations, Pain Management & Substance Use
13.1 Acute & Chronic Pain Management: Multimodal Analgesia & Opioid Stewardship 13.2 Substance Use Disorders: Opioid Agonist Therapy, Harm Reduction & Alcohol Withdrawal 13.3 Special Populations: Pharmacotherapy in Pregnancy, Lactation & Geriatrics (Deprescribing / Beers) 13.4 Palliative Care & Pediatric Pharmacotherapy
14 Chapter 14: Renal, Rheumatologic, Hematologic & Oncology Supportive Care
14.1 Chronic Kidney Disease, Acute Kidney Injury & Electrolyte Disorders 14.2 Osteoarthritis, Rheumatoid Arthritis & Gout 14.3 Anemias & Oncology Supportive Care
15 Chapter 15: Minor Ailments, Dermatology and Women's & Men's Health
15.1 Minor Ailments I: Allergic Rhinitis, Colds & Influenza, Eye and Ear Conditions 15.2 Minor Ailments II: Acne, Dermatitis, Psoriasis, Lice, Scabies & Sun Protection 15.3 Women's & Men's Health: Contraception, Emergency Contraception, Menopause, BPH, ED & Overactive Bladder
16 Chapter 16: Immunization & Health Promotion
16.1 Immunization Practice: NACI Recommendations, Administration, Cold Chain & Adverse Events 16.2 Health Promotion: Smoking Cessation, Weight Management, Screening & Social Determinants of Health
17 Chapter 17: Patient Care Process, Communication & Stewardship
17.1 The Patient Care Process: Assessment, Care Planning & Patient Interviewing 17.2 Patient Education, Device Counselling, Health Literacy & Overcoming Barriers 17.3 Interprofessional Collaboration, Pharmacy Workflow, Team Delegation & Drug Shortage Stewardship
5.3 Therapeutic Drug Monitoring (TDM), Narrow Therapeutic Index Drugs & Toxicities
Key Takeaways Explain This Topic AI
Therapeutic Drug Monitoring (TDM) is indicated for narrow therapeutic index (NTI) drugs exhibiting predictable concentration-response relationships, wide interindividual pharmacokinetic variability, and overlapping therapeutic and toxic serum thresholds.
Aminoglycosides (gentamicin, tobramycin) exhibit concentration-dependent bacterial killing ( C max / MIC ≥ 8 – 10 C_{\text{max}}/\text{MIC} \ge 8\text{--}10 C max / MIC ≥ 8 – 10 ) and a prolonged post-antibiotic effect (PAE); extended-interval once-daily dosing ( 5 – 7 mg/kg 5\text{--}7\text{ mg/kg} 5 – 7 mg/kg ) optimizes efficacy while minimizing nephrotoxicity and ototoxicity by allowing transient complete drug clearance (target trough < 1 mg/L < 1\text{ mg/L} < 1 mg/L , ideally < 0.5 mg/L < 0.5\text{ mg/L} < 0.5 mg/L ).
Vancomycin demonstrates time-dependent, concentration-independent bactericidal activity best predicted by the 24 24 24 -hour area under the curve to minimum inhibitory concentration ratio ( AUC 24 / MIC = 400 – 600 mg ⋅ h/L \text{AUC}_{24}/\text{MIC} = 400\text{--}600\text{ mg}\cdot\text{h/L} AUC 24 / MIC = 400 – 600 mg ⋅ h/L ), with Bayesian two-point modeling replacing conventional trough-only monitoring ( 15 – 20 mg/L 15\text{--}20\text{ mg/L} 15 – 20 mg/L ) to reduce acute kidney injury while ensuring clinical efficacy.
Total serum phenytoin (reference range 10 – 20 mg/L 10\text{--}20\text{ mg/L} 10 – 20 mg/L or 40 – 80 μ mol/L 40\text{--}80\ \mu\text{mol/L} 40 – 80 μ mol/L ) is 90 % 90\% 90% bound to albumin; in hypoalbuminemia ( < 40 g/L < 40\text{ g/L} < 40 g/L ) or end-stage renal disease, the Sheiner-Tozer equation ( C corrected = C measured 0.2 × Albumin (g/dL) + 0.1 C_{\text{corrected}} = \frac{C_{\text{measured}}}{0.2 \times \text{Albumin (g/dL)} + 0.1} C corrected = 0.2 × Albumin (g/dL) + 0.1 C measured or Canadian SI equivalents) or direct free phenytoin monitoring ( 1 – 2 mg/L 1\text{--}2\text{ mg/L} 1 – 2 mg/L ) must guide clinical decision-making.
Specific antidotes reverse acute life-threatening toxicities: naloxone for opioid-induced respiratory depression, flumazenil for benzodiazepines, N-acetylcysteine (NAC) for acetaminophen hepatotoxicity, digoxin immune fab for digitalis toxicity, idarucizumab for dabigatran, andexanet alfa for factor Xa inhibitors, protamine for unfractionated heparin, and vitamin K1 (phytonadione) for warfarin coagulopathy.
Last updated: October 2026
5.3 Therapeutic Drug Monitoring (TDM), Narrow Therapeutic Index Drugs & Toxicities
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring drug concentrations in biological fluids (serum, plasma, or whole blood) to guide individualized dosage adjustments. By linking quantified drug exposure to clinical pharmacodynamics, TDM maximizes therapeutic efficacy while preventing concentration-dependent toxicities.
Core Principles and Indications for TDM
Routine therapeutic drug monitoring is neither necessary nor cost-effective for the majority of pharmaceuticals. TDM is strictly indicated when a therapeutic agent satisfies five cardinal criteria:
Narrow Therapeutic Index (NTI) : A narrow margin exists between the minimum effective concentration ( M E C MEC MEC ) and the minimum toxic concentration ( M T C MTC MTC ). Small dosage changes can precipitate treatment failure or life-threatening toxicity.
Clear Concentration-Response Relationship : The pharmacological and toxicological effects correlate more strongly with circulating blood concentrations than with the administered dose.
Unpredictable Dose-Concentration Relationship : The drug displays substantial interindividual pharmacokinetic variability due to variable organ clearance, absorption differences, genetic polymorphisms, or capacity-limited non-linear elimination.
Absence of a Readily Measurable Clinical Surrogate Endpoint : Unlike antihypertensives (where blood pressure is directly measured) or anticoagulants (where INR or anti-Xa is measured), the desired clinical effect (e.g., seizure suppression, infection clearance, mood stabilization) cannot be assessed instantly with a routine bedside test.
Validated Analytical Assay Availability : Accurate, standardized laboratory assays with established therapeutic reference ranges must be clinically accessible.
Timing of Blood Sampling: Troughs, Peaks & Steady State
Drawing a blood sample at the incorrect time invalidates the laboratory result and can lead to dangerous dosing miscalculations:
Trough Concentration ( C min C_{\text{min}} C min ) : The lowest drug concentration during the dosing interval, drawn immediately prior to the next scheduled dose (ideally within 30 minutes 30\text{ minutes} 30 minutes before administration). Troughs assess drug accumulation, clearance, and safety.
Peak Concentration ( C max C_{\text{max}} C max ) : The highest drug concentration achieved after the completion of drug absorption and post-infusion distribution phase :
IV Aminoglycosides : Drawn 30 minutes 30\text{ minutes} 30 minutes after the end of a 30 30 30 -minute IV infusion (or 60 minutes after the start of infusion) to ensure distribution from the central compartment into tissue spaces is complete.
IV Vancomycin : Drawn 1 to 2 hours 1\text{ to }2\text{ hours} 1 to 2 hours after the end of the IV infusion to allow completion of the multi-compartment tissue distribution phase.
Oral Digoxin : Drawn at least 6 to 8 hours 6\text{ to }8\text{ hours} 6 to 8 hours post-dose (or immediately prior to the next dose) because digoxin exhibits a prolonged 6 6 6 - to 8 8 8 -hour tissue distribution phase into myocardial binding sites; levels drawn earlier reflect falsely elevated plasma levels that do not correlate with tissue response.
Requirement for Steady State : Blood samples for routine dosage adjustments must be obtained at steady state (after 4 to 5 4\text{ to }5 4 to 5 elimination half-lives of constant dosing), unless acute toxicity is suspected or early pharmacokinetic modeling (e.g., aminoglycoside Hartford nomogram) is specifically utilized.
Aminoglycosides: Gentamicin, Tobramycin & Amikacin
Aminoglycosides are bactericidal antibiotics targeting the bacterial 30 S 30\text{S} 30 S ribosomal subunit, primarily active against aerobic Gram-negative bacilli ( Pseudomonas aeruginosa , Enterobacterales ):
Pharmacodynamic Profile
Concentration-Dependent Killing : Antibacterial efficacy is driven by the ratio of peak concentration to the minimum inhibitory concentration ( Peak / MIC \text{Peak}/\text{MIC} Peak / MIC or C max / MIC C_{\text{max}}/\text{MIC} C max / MIC ). Optimal bactericidal killing requires a C max / MIC ≥ 8 – 10 C_{\text{max}}/\text{MIC} \ge 8\text{--}10 C max / MIC ≥ 8 – 10 .
Post-Antibiotic Effect (PAE) : Aminoglycosides produce prolonged persistent suppression of bacterial growth for several hours even after serum concentrations drop far below the MIC.
Adaptive Resistance Prevention : High transient peak concentrations prevent the emergence of adaptive bacterial resistance.
Extended-Interval (Once-Daily) Dosing vs. Traditional Dosing
Dosing Modality Standard Dose & Frequency Target Peak Target Trough Clinical Rationale & Monitoring
Extended-Interval (Once-Daily) 5 – 7 mg/kg 5\text{--}7\text{ mg/kg} 5 – 7 mg/kg IV every 24 hours (or Q36H/Q48H in renal impairment) 16 – 24 mg/L 16\text{--}24\text{ mg/L} 16 – 24 mg/L Undetectable / < 0.5 – 1.0 mg/L < 0.5\text{--}1.0\text{ mg/L} < 0.5 – 1.0 mg/L Maximizes C max / MIC ≥ 10 C_{\text{max}}/\text{MIC} \ge 10 C max / MIC ≥ 10 ; drug-free period allows renal proximal tubule and inner ear cells to clear intracellular drug, saturating uptake and minimizing toxicity. Monitored via Hartford Nomogram (random level drawn 6–14 hours post-start of infusion).
Traditional Multiple-Daily 1.5 – 2.0 mg/kg 1.5\text{--}2.0\text{ mg/kg} 1.5 – 2.0 mg/kg IV every 8 hours 5 – 10 mg/L 5\text{--}10\text{ mg/L} 5 – 10 mg/L ( 20 – 30 mg/L 20\text{--}30\text{ mg/L} 20 – 30 mg/L for Amikacin) < 2 mg/L < 2\text{ mg/L} < 2 mg/L ( < 1 mg/L < 1\text{ mg/L} < 1 mg/L preferred; < 5 mg/L < 5\text{ mg/L} < 5 mg/L for Amikacin) Reserved for synergy in Gram-positive enterococcal/streptococcal endocarditis, pregnancy, extensive burns, severe ascites, or severe renal impairment ( CrCl < 30 mL/min \text{CrCl} < 30\text{ mL/min} CrCl < 30 mL/min ).
Toxicities
Nephrotoxicity : Non-oliguric acute tubular necrosis (ATN) resulting from progressive accumulation in proximal tubular lysosomes. Characterized by rising serum creatinine, granular casts, and proteinuria. Typically reversible upon drug cessation.
Ototoxicity : Accumulates in the endolymph and perilymph of the inner ear, destroying sensory hair cells. Manifests as vestibular toxicity (vertigo, ataxia, loss of balance) and cochlear toxicity (tinnitus, irreversible high-frequency sensorineural hearing loss). Frequently irreversible !
Neuromuscular Blockade : Rare, life-threatening inhibition of presynaptic acetylcholine release and postsynaptic receptor blockade, precipitating respiratory arrest; exacerbated by neuromuscular blockers or myasthenia gravis (reversal: IV calcium gluconate).
Vancomycin: The Modern AUC/MIC Paradigm
Vancomycin is a glycopeptide antibiotic that binds D-Ala-D-Ala terminals of peptidoglycan precursors, inhibiting cell wall synthesis in Gram-positive organisms (including Methicillin-Resistant Staphylococcus aureus [MRSA]).
PK/PD Efficacy Target: AUC 24 / MIC \text{AUC}_{24}/\text{MIC} AUC 24 / MIC
Vancomycin exhibits time-dependent, concentration-independent bactericidal activity . The primary pharmacokinetic parameter predicting clinical success and bacterial eradication is the ratio of the 24 24 24 -hour area under the curve to the minimum inhibitory concentration:
AUC 24 MIC = 400 to 600 mg ⋅ h/L \frac{\text{AUC}_{24}}{\text{MIC}} = 400\text{ to }600\text{ mg}\cdot\text{h/L} MIC AUC 24 = 400 to 600 mg ⋅ h/L
(Assuming a standard broth microdilution MIC ≤ 1 mg/L \text{MIC} \le 1\text{ mg/L} MIC ≤ 1 mg/L ).
Important
The Paradigm Shift Away from Trough-Only Monitoring :
Historically, clinicians relied on trough concentrations of 15 to 20 mg/L 15\text{ to }20\text{ mg/L} 15 to 20 mg/L as a surrogate for serious MRSA infections (bacteremia, endocarditis, osteomyelitis, pneumonia). However, contemporary consensus guidelines (IDSA, ASHP) establish that troughs > 15 mg/L >15\text{ mg/L} > 15 mg/L are independently associated with significant acute kidney injury (AKI) without improving clinical cure rates compared to an AUC of 400 – 600 mg ⋅ h/L 400\text{--}600\text{ mg}\cdot\text{h/L} 400 – 600 mg ⋅ h/L . Current standard practice recommends Bayesian software estimation or two-point pharmacokinetic sampling (a post-infusion peak drawn 1 – 2 1\text{--}2 1 – 2 hours after infusion and a trough drawn prior to the next dose) to maintain AUC 24 / MIC \text{AUC}_{24}/\text{MIC} AUC 24 / MIC between 400 400 400 and 600 mg ⋅ h/L 600\text{ mg}\cdot\text{h/L} 600 mg ⋅ h/L , keeping troughs lower ( 10 – 15 mg/L 10\text{--}15\text{ mg/L} 10 – 15 mg/L ) and sparing renal function.
Vancomycin Toxicities & Infusion Reactions
Nephrotoxicity : Acute tubular necrosis and acute interstitial nephritis; risk escalates with AUC > 600 mg ⋅ h/L > 600\text{ mg}\cdot\text{h/L} > 600 mg ⋅ h/L , sustained troughs > 20 mg/L >20\text{ mg/L} > 20 mg/L , therapy > 7 >7 > 7 days, and concurrent nephrotoxins (especially piperacillin/tazobactam ).
Vancomycin Infusion Reaction (historically "Red Man Syndrome") : An immediate, non-IgE-mediated, rate-dependent pseudoallergic reaction caused by direct degranulation of mast cells and basophils, releasing histamine. Symptoms include erythematous flushing, pruritus, tingling, and an erythematous maculopapular rash across the face, neck, and upper torso, occasionally accompanied by hypotension.
Prevention & Management : Infuse vancomycin slowly at a rate ≤ 1 , 000 mg \le 1,000\text{ mg} ≤ 1 , 000 mg over at least 60 minutes 60\text{ minutes} 60 minutes (or ≤ 10 mg/min \le 10\text{ mg/min} ≤ 10 mg/min for doses > 1 , 000 mg >1,000\text{ mg} > 1 , 000 mg ). If the reaction occurs, stop the infusion, administer an oral or IV H 1 \text{H}_1 H 1 -antihistamine (diphenhydramine 50 mg 50\text{ mg} 50 mg ) and H 2 \text{H}_2 H 2 -antagonist (famotidine), wait for symptom resolution, and restart the infusion at half the original rate.
Phenytoin: Protein Binding & The Sheiner-Tozer Correction
Phenytoin is a narrow therapeutic index hydantoin antiseizure medication used in focal and generalized status epilepticus:
Therapeutic Reference Range : Total Phenytoin = 10 to 20 mg/L = 10\text{ to }20\text{ mg/L} = 10 to 20 mg/L ( 40 to 80 μ mol/L 40\text{ to }80\ \mu\text{mol/L} 40 to 80 μ mol/L ).
Free (Unbound) Phenytoin Range : Free Phenytoin = 1 to 2 mg/L = 1\text{ to }2\text{ mg/L} = 1 to 2 mg/L ( 4 to 8 μ mol/L 4\text{ to }8\ \mu\text{mol/L} 4 to 8 μ mol/L ).
Protein Binding Displacement Dynamics
In healthy adults, phenytoin is approximately 90 % 90\% 90% bound to plasma albumin ; only the remaining 10 % 10\% 10% free fraction ( f u = 0.10 f_u = 0.10 f u = 0.10 ) cross the blood-brain barrier to exert anticonvulsant activity and undergo hepatic metabolism. In patients with hypoalbuminemia (serum albumin < 40 g/L < 40\text{ g/L} < 40 g/L or < 4.0 g/dL < 4.0\text{ g/dL} < 4.0 g/dL ) or end-stage renal disease (ESRD) , the free fraction increases substantially. The measured total phenytoin level appears falsely low, while the active free level remains therapeutic or toxic.
The Sheiner-Tozer Equations
When free phenytoin levels are unavailable, pharmacists calculate the adjusted (corrected) total phenytoin concentration :
In Canadian SI units (Albumin in g/L \text{g/L} g/L , where normal albumin is ≈ 40 g/L \approx 40\text{ g/L} ≈ 40 g/L ):
C corrected = C measured 0.02 × Albumin (g/L) + 0.1 C_{\text{corrected}} = \frac{C_{\text{measured}}}{0.02 \times \text{Albumin (g/L)} + 0.1} C corrected = 0.02 × Albumin (g/L) + 0.1 C measured
When Albumin is reported in conventional units ( g/dL \text{g/dL} g/dL ):
C corrected = C measured 0.2 × Albumin (g/dL) + 0.1 C_{\text{corrected}} = \frac{C_{\text{measured}}}{0.2 \times \text{Albumin (g/dL)} + 0.1} C corrected = 0.2 × Albumin (g/dL) + 0.1 C measured
In End-Stage Renal Disease ( CrCl < 15 mL/min \text{CrCl} < 15\text{ mL/min} CrCl < 15 mL/min or hemodialysis), uremic toxins displace phenytoin from albumin binding sites, further reducing affinity:
C corrected, ESRD = C measured 0.01 × Albumin (g/L) + 0.1 ( or C measured 0.1 × Albumin (g/dL) + 0.1 ) C_{\text{corrected, ESRD}} = \frac{C_{\text{measured}}}{0.01 \times \text{Albumin (g/L)} + 0.1} \quad \left(\text{or } \frac{C_{\text{measured}}}{0.1 \times \text{Albumin (g/dL)} + 0.1}\right) C corrected, ESRD = 0.01 × Albumin (g/L) + 0.1 C measured ( or 0.1 × Albumin (g/dL) + 0.1 C measured )
Concentration-Dependent Phenytoin Toxicity
> 20 mg/L > 20\text{ mg/L} > 20 mg/L ( > 80 μ mol/L > 80\ \mu\text{mol/L} > 80 μ mol/L ) : Lateral gaze nystagmus
> 30 mg/L > 30\text{ mg/L} > 30 mg/L ( > 120 μ mol/L > 120\ \mu\text{mol/L} > 120 μ mol/L ) : Ataxia, slurred speech, dysarthria, nausea, vomiting
> 40 mg/L > 40\text{ mg/L} > 40 mg/L ( > 160 μ mol/L > 160\ \mu\text{mol/L} > 160 μ mol/L ) : Lethargy, stupor, confusion, coma, paradoxical encephalopathic seizures
Chronic Effects : Gingival hyperplasia, hirsutism, peripheral neuropathy, coarsening of facial features, osteomalacia, folate deficiency.
Lithium
Lithium carbonate is a monovalent cation used in bipolar affective disorder for acute mania and maintenance mood stabilization:
Therapeutic Reference Range :
Acute Mania : 0.8 to 1.2 mmol/L 0.8\text{ to }1.2\text{ mmol/L} 0.8 to 1.2 mmol/L
Maintenance Therapy : 0.6 to 0.8 mmol/L 0.6\text{ to }0.8\text{ mmol/L} 0.6 to 0.8 mmol/L (rarely up to 1.0 mmol/L 1.0\text{ mmol/L} 1.0 mmol/L )
Sampling Timing : Standard 12-hour trough drawn in the morning, exactly 12 hours after the evening dose at steady state.
Renal Mechanics and Drug Interactions
Lithium is not metabolized; it is eliminated entirely by renal glomerular filtration. In the renal proximal tubule, lithium is handled identically to sodium, with 80 % 80\% 80% of filtered lithium reabsorbed alongside sodium :
Sodium Depletion / Volume Contraction : When the body experiences sodium or water depletion (dehydration, vomiting, diarrhea, intense sweating, sodium-restricted diet), the proximal tubule compensatorily increases sodium and water reabsorption, simultaneously reabsorbing lithium , rapidly driving serum lithium into toxic ranges.
Interacting Drug Class Representative Agents Mechanism of Interaction Clinical Consequence & Action
Thiazide Diuretics Hydrochlorothiazide, Chlorthalidone, Indapamide Block Na + / Cl − \text{Na}^+/\text{Cl}^- Na + / Cl − cotransporter in distal tubule → \rightarrow → mild volume depletion → \rightarrow → massive compensatory proximal reabsorption of sodium and lithium Plummets lithium clearance by 25 % – 40 % 25\%\text{--}40\% 25% – 40% ; severe lithium toxicity. Reduce lithium dose by 50 % 50\% 50% or avoid combination.
ACE Inhibitors & ARBs Ramipril, Perindopril, Enalapril, Candesartan Inhibit angiotensin II → \rightarrow → efferent arteriolar vasodilation → \rightarrow → decreased GFR and altered tubular sodium transport Decreases lithium clearance over several weeks; monitor lithium levels closely and reduce dose.
NSAIDs Ibuprofen, Naproxen, Celecoxib, Indomethacin Inhibit renal prostaglandins → \rightarrow → constrict afferent arterioles → \rightarrow → reduce GFR and lithium clearance Elevates lithium levels by 10 % – 40 % 10\%\text{--}40\% 10% – 40% . (Aspirin and sulindac appear to have lower interaction risk).
Symptoms of Lithium Toxicity
Mild ( 1.5 – 2.0 mmol/L 1.5\text{--}2.0\text{ mmol/L} 1.5 – 2.0 mmol/L ) : Coarse hand tremor, persistent diarrhea, nausea, vomiting, muscle weakness, lethargy.
Moderate ( 2.0 – 2.5 mmol/L 2.0\text{--}2.5\text{ mmol/L} 2.0 – 2.5 mmol/L ) : Hyperreflexia, ataxia, dysarthria, blurred vision, clonic movements, confusion.
Severe ( > 2.5 mmol/L > 2.5\text{ mmol/L} > 2.5 mmol/L ) : Delirium, seizures, stupor, cardiovascular collapse, permanent cerebellar and cognitive impairment ( SILENT syndrome —Syndrome of Irreversible Lithium-Effectuated Neurotoxicity).
Management : Aggressive IV hydration with Normal Saline ( 0.9 % NaCl 0.9\%\ \text{NaCl} 0.9% NaCl ) to restore intravascular volume and promote renal lithium clearance. The EXTRIP workgroup recommends hemodialysis when kidney function is impaired and lithium exceeds 4.0 mmol/L 4.0\text{ mmol/L} 4.0 mmol/L , or when there is decreased consciousness, seizures or a life-threatening dysrhythmia at any level. It suggests dialysis when lithium exceeds 5.0 mmol/L 5.0\text{ mmol/L} 5.0 mmol/L , when there is significant confusion, or when lithium is expected to take more than 36 hours to fall below 1.0 mmol/L 1.0\text{ mmol/L} 1.0 mmol/L with optimal management.
Digoxin
Digoxin is a cardiac glycoside that inhibits myocardial Na + / K + \text{Na}^+/\text{K}^+ Na + / K + -ATPase, increasing intracellular calcium to enhance inotropy and vagally blunting AV node conduction:
Therapeutic Reference Range :
Heart Failure with Reduced Ejection Fraction (HFrEF) : 0.5 to 0.9 ng/mL 0.5\text{ to }0.9\text{ ng/mL} 0.5 to 0.9 ng/mL ( 0.6 to 1.2 nmol/L 0.6\text{ to }1.2\text{ nmol/L} 0.6 to 1.2 nmol/L ). Levels > 1.0 ng/mL >1.0\text{ ng/mL} > 1.0 ng/mL provide zero additional inotropic benefit but significantly increase all-cause mortality!
Atrial Fibrillation Rate Control : 0.8 to 2.0 ng/mL 0.8\text{ to }2.0\text{ ng/mL} 0.8 to 2.0 ng/mL ( 1.0 to 2.6 nmol/L 1.0\text{ to }2.6\text{ nmol/L} 1.0 to 2.6 nmol/L ).
Sampling Timing : Serum levels must be drawn at least 6 to 8 hours 6\text{ to }8\text{ hours} 6 to 8 hours post-dose to allow complete myocardial tissue equilibration.
The Electrolyte Triad Potentiating Digoxin Toxicity
Hypokalemia : Extracellular potassium and digoxin compete for the same binding site on the Na + / K + \text{Na}^+/\text{K}^+ Na + / K + -ATPase pump. When serum potassium falls below 4.0 mmol/L 4.0\text{ mmol/L} 4.0 mmol/L , more ATPase sites are left open for digoxin binding, precipitating severe life-threatening digitalis toxicity even when serum digoxin levels are within the normal reference range !
Hypomagnesemia : Impairs Na + / K + \text{Na}^+/\text{K}^+ Na + / K + -ATPase function, directly promoting digitalis arrhythmias.
Hypercalcemia : Synergizes with digoxin to overload intracellular cardiac calcium stores, precipitating fatal ventricular tachyarrhythmias.
Digoxin Toxicity Manifestations
Gastrointestinal : Anorexia (earliest sign), nausea, vomiting, abdominal discomfort.
Visual : Xanthopsia (yellow-green color halos around lights), photophobia, blurred vision, scotomas.
Cardiac : Sinus bradycardia, high-degree AV block, premature ventricular contractions (bigeminy), bidirectional ventricular tachycardia, ventricular fibrillation. Classic ECG sign: "scooped" ST-segment depression (digitalis effect, not necessarily toxicity).
Clinical Toxicology and Specific Reversal Antidotes
When acute drug overdose or life-threatening adverse drug events occur, pharmacists must immediately recommend evidence-based reversal strategies and specific antidotes:
Toxin / Medication Specific Antidote Mechanism of Action Clinical Pearls & Administration Rules
Acetaminophen (APAP) N-Acetylcysteine (NAC) (IV or Oral) Replenishes hepatic glutathione stores and acts as an alternate substrate to conjugate and neutralize toxic NAPQI Administer based on the Rumack-Matthew Nomogram for single acute ingestions starting 4 hours post-ingestion. Nearly 100 % 100\% 100% hepatoprotective if started within 8 hours of ingestion. Continue until serum APAP is undetectable and transaminases are normalizing.
Opioids Naloxone (IV, IM, SC, Intranasal) Competitive pure mu-opioid receptor antagonist Titrate to restore spontaneous ventilation, not full alertness (avoid precipitating severe acute withdrawal). Elimination half-life of naloxone is short ( 30 – 90 minutes 30\text{--}90\text{ minutes} 30 – 90 minutes ); long-acting opioids (Methadone, slow-release morphine) require repeated boluses or a continuous IV naloxone infusion.
Benzodiazepines Flumazenil (IV) Competitive antagonist at the benzodiazepine recognition site on the GABA A \text{GABA}_A GABA A receptor High-Risk Antidote : Use with extreme caution. Contraindicated in chronic benzodiazepine users (precipitates refractory status epilepticus) or co-ingestion of proconvulsant agents (Tricyclic Antidepressants, Bupropion). Reserved primarily for procedural sedation reversal.
Digoxin Digoxin Immune Fab (DigiFab) (IV) Antigen-binding fragments of anti-digoxin antibodies that bind free intravascular digoxin Indicated for life-threatening arrhythmias, severe hyperkalemia ( K + > 5.0 mmol/L K^+ > 5.0\text{ mmol/L} K + > 5.0 mmol/L in acute ingestion), or acute ingestion > 10 mg >10\text{ mg} > 10 mg in adults. Once DigiFab is given, total serum digoxin levels become falsely markedly elevated on standard immunoassays (measuring bound inactive Fab complexes) and must not be monitored.
Dabigatran Idarucizumab (Praxbind) (IV) Humanized monoclonal antibody fragment (Fab) that binds free and thrombin-bound dabigatran with 350 × 350\times 350 × higher affinity than thrombin Dosed as 5 g 5\text{ g} 5 g IV ( 2 × 2.5 g 2 \times 2.5\text{ g} 2 × 2.5 g vials). Produces immediate and complete reversal of dabigatran anticoagulation within minutes for emergency surgery or life-threatening hemorrhage.
Factor Xa Inhibitors (Apixaban, Rivaroxaban, Edoxaban) Andexanet alfa (Ondexxya) or 4-Factor Prothrombin Complex Concentrate (4F-PCC) Decoy recombinant modified human Factor Xa protein (Andexanet alfa) or replacement of vitamin K-dependent factors II, VII, IX, X (4F-PCC) In Canadian practice, 4F-PCC (Octaplex, Beriplex; 25 – 50 units/kg 25\text{--}50\text{ units/kg} 25 – 50 units/kg ) is widely used off-label for urgent factor Xa inhibitor major bleeding due to rapid availability and cost parameters.
Unfractionated Heparin (UFH) Protamine Sulfate (IV) Strongly basic polycationic protein that complexes with strongly acidic polyanionic heparin to form an inactive salt 1 mg 1\text{ mg} 1 mg of protamine neutralizes ≈ 100 units \approx 100\text{ units} ≈ 100 units of heparin remaining in the body. Maximum single dose 50 mg 50\text{ mg} 50 mg infused slowly over 10 minutes (rapid infusion causes severe hypotension and anaphylactoid shock).
Low Molecular Weight Heparin (Enoxaparin) Protamine Sulfate (IV) Partially neutralizes anti-IIa activity and ≈ 60 % \approx 60\% ≈ 60% of anti-Xa activity 1 mg 1\text{ mg} 1 mg protamine per 1 mg 1\text{ mg} 1 mg of enoxaparin administered within past 8 hours. Complete reversal is not achieved.
Warfarin Vitamin K1 (Phytonadione) (Oral or IV) + 4F-PCC for major bleeding Phytonadione bypasses epoxide reductase to drive hepatic synthesis of active factors II, VII, IX, X; 4F-PCC replaces factors immediately For life-threatening bleeding: 4F-PCC ( 25 – 50 units/kg 25\text{--}50\text{ units/kg} 25 – 50 units/kg ) + IV Vitamin K1 10 mg 10\text{ mg} 10 mg in 50 mL 50\text{ mL} 50 mL NS infused over 20 minutes. Avoid SC/IM routes (erratic absorption and hematoma risk). For asymptomatic elevated INR: oral vitamin K1 is preferred over IV.
Toxic Alcohols (Methanol, Ethylene Glycol) Fomepizole (4-methylpyrazole) or Ethanol Potent competitive inhibitor of alcohol dehydrogenase (ADH) , preventing conversion into toxic organic acids (formic acid, glycolic/oxalic acid) Fomepizole is preferred over IV ethanol due to ease of dosing, lack of CNS depression, and predictable kinetics. Hemodialysis is added if severe anion gap metabolic acidosis or end-organ damage is present.
Beta-Blockers High-Dose Insulin Euglycemia Therapy (HIET) + Glucagon + IV Calcium HIET enhances myocardial carbohydrate uptake and cardiac inotropy; Glucagon stimulates adenylate cyclase via non-adrenergic receptors High-dose regular insulin ( 1 unit/kg 1\text{ unit/kg} 1 unit/kg IV bolus followed by 0.5 – 1.0 units/kg/hr 0.5\text{--}1.0\text{ units/kg/hr} 0.5 – 1.0 units/kg/hr infusion) with dextrose 10 % – 50 % 10\%\text{--}50\% 10% – 50% and potassium titration.
Calcium Channel Blockers HIET + IV Calcium Chloride/Gluconate + IV Lipid Emulsion Overcomes myocardial metabolic starvation; increases extracellular calcium gradient High-dose insulin is first-line; IV lipid emulsion ( 20 % 20\% 20% Intralipid) acts as a "lipid sink" for lipophilic CCBs (Verapamil, Diltiazem).
Anticholinergic Delirium (Atropine, Diphenhydramine, Scopolamine) Physostigmine (IV) Reversible acetylcholinesterase inhibitor that readily crosses the blood-brain barrier to restore central acetylcholine Indicated for severe central anticholinergic delirium/agitation. Contraindicated in suspected TCA overdose (causes cardiac asystole).